Adamis Pharmaceuticals Announces License Agreement with Allergan plc Subsidiary for Epinephrine Pre-Filled Syringe

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. META
3. ABBV
4. SPY
5. FDX
6. IBM
7. MU
8. ACN
9. USO
10. NVDA

Go back to Adamis Pharmaceuticals Announces License Agreement with Allergan plc Subsidiary for Epinephrine Pre-Filled Syringe

Piper Jaffray Remains Sidelined on Teva Pharma (TEVA) Following 1Q - PT to $58

May 10, 2016 8:04 AM EDT

Piper Jaffray maintained a Neutral rating on Teva Pharma (NYSE: TEVA), and cut the price target to $58.00 (from $59.00), following the company's 1Q earnings report. TEVA reported a non-GAAP EPS of $1.20 on revenues of $4.81B, ahead of the Street's estimates of $1.17 and $4.77B, respectively. Management noted that companies with older, more commodity-focused portfolios should expect... More